AbbVie Inc.
ABBV
Classificação em ações
#25
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Preço da ação
$282.96
Última sincronização: 2026-10-19
Valor de mercado
$500.02B
Variação (1 dia)
-0.75%
Variação (1 ano)
22.62%
País
US
Negociar AbbVie Inc. (ABBV)
Categoria
Healthcare
Histórico de desdobramentos de ações de AbbVie Inc. (ABBV)
As ações AbbVie Inc. (símbolo: ABBV) passaram por um total de 0 desdobramentos.
O desdobramento mais recente ocorreu em Oct 20, 2026.
Uma ação ABBV comprada antes de Oct 20, 2026 equivaleria hoje a 0 ações ABBV.
O desdobramento mais recente ocorreu em Oct 20, 2026.
Uma ação ABBV comprada antes de Oct 20, 2026 equivaleria hoje a 0 ações ABBV.
Lista de desdobramentos de ações
| Ano | Desdobramento | Multiplicador | Multiplicador cumulativo |
|---|---|---|---|
| Não há dados suficientes para as datas fornecidas. | |||
Desdobramentos de ações de empresas semelhantes ou concorrentes
| Empresa | Número de desdobramentos de ações | Multiplicador cumulativo | País |
|---|---|---|---|
| 4 | x15 |
US
|
|
| 7 | x432 |
US
|
|
| 7 | x226 |
US
|
|
| 2 | x10000 |
CH
|
|
| 2 | x47 |
CH
|
